Swiss-American medical company Alcon Inc. has signed an agreement to acquire Staar Surgical Co. for $1.5 billion. This is reported in a press release from Alcon.
The transaction price is $28 per Staar share (51% higher than the closing price on August 4, 2025). The financing of the transaction involves the attraction of borrowed funds.
The deal is the largest for Alcon since its separation from Novartis AG in 2019 and is aimed at expanding the company's presence in the refractive lenses and surgical vision correction sector through Staar technologies, including lenses that complement Alcon's line of lasers designed for patients with various forms of myopia.
The transaction is expected to be completed in 6-12 months. From the point of view of the STAAR board of directors, the value of the transaction exceeds the capabilities of the independent strategy of STAAR, which has suffered losses amid fluctuations in demand in China over the past two years.
Staar Surgical is an American ophthalmological company developing technologies for vision correction through the use of implantable collimator lenses (ICLs), which can be implemented as part of a minimally invasive procedure. The company offers a wide range of technologies for correcting refractive disorders (nearsightedness, farsightedness and astigmatism), including intraocular lenses for cataract surgery and devices for the treatment of glaucoma. The headquarters is located in Monrovia, California.
Alcon is a Swiss-American medical company that manufactures equipment and drugs for the ophthalmology sector. The headquarters is located in Geneva (Switzerland) with the main operational office in Fort Worth (Texas).
Read also in our Telegram channel "Mergers and acquisitions. AK&M»
